QL Biopharm

Based in Beijing, China and established in 2018, Beijing QL Biopharmaceutical Co. , Ltd. , trading as QL Biopharm, operates as a recombinant protein drug provider, focusing on the production of recombinant protein drugs. Xujia Zhang, the founder and the CEO of the company, was a researcher at the Institute of Biophysics, Chinese Academy of Sciences.

The core members of the company's research and development team used to work at Novo Nordisk, Gan & Lee and other pharmaceutical companies. QL Biopharm has established a research and development center in Beijing and a production base in Taizhou, China. It was awarded honors such as Specialized, Refined, Featured and Original SMEs in Beijing and National High-tech Enterprise. In March 2026, QL Biopharm raised over CNY 500 million in Series C funding led by OrbiMed Advisors, with participation from 5Y Capital, Apricot Capital, Huagai Capital, Qiming Venture Partners, TigerYeah Capital, Lanchi Ventures and TF Capital.

The company's technology platforms include QL Fold, QL Long, QL Fusion and QL Oral. The company has 10 recombinant protein innovators and biosimilars under development in its product pipeline, including two international class I innovators and one large biosimilar. QL Biopharm's drugs can be used to treat diabetes, obesity, non-alcoholic steatohepatitis and other diseases. The company generates revenue from providing recombinant protein drugs.